SciELO - Scientific Electronic Library Online

 
vol.8 issue3Sleep disorder brething inHeart Failure with reduced ejection fraction.COVID-19 and Systemic Autoimmune Diseases, what is the relationship and its consequences? author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Related links

Share


Revista Uruguaya de Medicina Interna

On-line version ISSN 2393-6797

Abstract

CAMEJO, Natalia et al. Clinical-pathological characteristics and evolution of breast cancer in patients assisted in the Mastology Unit of the Hospital de Clínicas. Rev. Urug. Med. Int. [online]. 2023, vol.8, n.3, pp.16-25.  Epub Dec 01, 2023. ISSN 2393-6797.  https://doi.org/10.26445/08.03.2.

Introduction:

In Uruguay, breast cancer (BC) ranks first in incidence and mortality from cancer in women. It is a multifactorial disease that is related to genetic inheritance, estrogenic hormonal history, lifestyle, environmental and cultural factors.

Objectives:

to investigate the clinicopathological characteristics of patients with BC diagnosed at the Hospital de Clínicas and to evaluate the overall overall survival (SVG) and according to the biological subtype.

Metodology:

data related to the clinicopathological characteristics and the evolution of patients treated for BC in the period between January 1, 2011 and December 31, 2020 assisted in the Mastology Unit of the Hospital de Clínicas were collected. Overall survival (SVG) was calculated for all patients, globally, and according to biological subtype.

Results:

390 patients were included. The clinicopathological characteristics were: ductal carcinoma: 83%, stage: in situ (1.8%), I (27.7%), II (29.7%), III (23.6%), IV (12.6%). Regarding the biological profile: 235 tumors (60.3%) were HR+ HER 2−, 88 tumors (22.6%) were HER2 +, while another 41 tumors (10.5%) were classified as triple negative (TN). The SVG for all the patients had a median of 92 months. SVG rates at 2 and 5 years were 92% and 64% for luminals; in TN the 24-month survival rate was 69%, being 53.3% at 5 years and in HER2 + 76.6% and 67.3% respectively.

Conclusions:

Most of the tumors were diagnosed in early stages, these data being consistent with those reported in studies carried out at the national level. The frequency of ER/RP+ tumors was somewhat lower than that reported in previous studies (70%) at the national level, while that of HER 2 + TN tumors was similar to that reported in European, North American and Latin American studies where the prevalence found is 20%

Keywords : Neoplasms of the breast; Clinicopathological features; Survived.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )